SEC Company Response from Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — Apr 7, 2017
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: April 7, 2017 · CIK: 0001506251 · Accession: 0001477932-17-001627
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-216030
Letter
ctxr_corresp.htmCITIUS PHARMACEUTICALS, INC.
11 Commerce Drive, First Floor
Cranford, New Jersey 07016
April 7, 2017
Via EDGAR Delivery
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Christine Westbrook
Re: Citius Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-216030
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Citius Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) to April 11, 2017 at 5:00 p.m. Eastern Time, or as soon thereafter as practicable.
In connection with the foregoing, the Registrant hereby acknowledges the following:
· should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
· the Registrant will not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Erica Jackson at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Ms. Jackson via email at ejackson@wyrick.com.
Very truly yours,
CITIUS PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm ctxr_corresp.htmCITIUS PHARMACEUTICALS, INC. 11 Commerce Drive, First Floor Cranford, New Jersey 07016 April 7, 2017 Via EDGAR Delivery Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Christine Westbrook Re: Citius Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-216030 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Citius Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) to April 11, 2017 at 5:00 p.m. Eastern Time, or as soon thereafter as practicable. In connection with the foregoing, the Registrant hereby acknowledges the following: · should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and · the Registrant will not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Erica Jackson at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Ms. Jackson via email at ejackson@wyrick.com. Very truly yours, CITIUS PHARMACEUTICALS, INC. By: /s/ Myron Holubiak Myron Holubiak Chief Executive Officer